Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

Nine studies (6 randomized controlled trials and 3 prospective comparative studies) were selected to examine the effects of leukocyte-poor platelet rich plasma and leukocyte-rich platelet rich plasma in knee osteoarthritis treatment. Due to the presence of only one direct comparison between LP-PRP and LR-PRP at the time of the study, studies which compared either to hyaluronic or placebo were included, and network meta-analysis was undertaken. Primary outcome was the incidence of local adverse events, while secondary efficacy outcomes included the change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and International Knee Documentation Committee (IKDC) scores. Incidence of local adverse events was higher with LP-PRP or LR-PRP compared to HA or placebo, and both were ranked at approximately 20% of being the best treatment for the outcome. Nevertheless, the difference between LP-PRP and LR-PRP for incidence of local adverse events was not significant. LP-PRP was ranked number one when considering effect on change in WOMAC, with a 98% probability of being considered the best treatment for the outcome.